TY - JOUR
T1 - Prognostic significance of tumor immunity in surgically resected pulmonary pleomorphic carcinoma
AU - Kaira, Kyoichi
AU - Shimizu, Kimihiro
AU - Endoh, Hideki
AU - Imaizumi, Kazuyoshi
AU - Kamiyoshihara, Mitsuhiro
AU - Sugano, Masayuki
AU - Kawashima, Osamu
AU - Tanaka, Shigefumi
AU - Fujita, Atsushi
AU - Imai, Hisao
AU - Kogure, Yoshihito
AU - Oyama, Tetsunari
AU - Asao, Takayuki
AU - Shirabe, Ken
N1 - Funding Information:
KK has received research grants and a speaker honorarium from Boehringer Ingelheim Company, Ono Pharmaceutical Company, and Bristol-Myers Company and Chugai Pharmaceutical Company, and KS has received research grants and a speaker honorarium from Ono Pharmaceutical Company and Chugai Pharmaceutical Company. All remaining Authors have declared no conflicts of interest.
Funding Information:
1Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan; 2Department of Innovative Immune-Oncology Therapeutics, Gunma University, Graduate School of Medicine, Maebashi, Japan; 3Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan; 4Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, Saku, Japan; 5Department of Respiratory Medicine, Fujita Health University, Toyoake, Japan; 6Department of General Thoracic Surgery, Japanese Red Cross Maebashi Hospital, Maebashi, Japan; 7Department of Respiratory Surgery, Takasaki Medical Center, Takasaki, Japan; 8Department of Respiratory Surgery, Shibukawa Medical Center, Shibukawa, Japan; 9Department of Respiratory Surgery, Isesaki Municipal Hospital, Isesaki, Japan; 10Division of Thoracic Surgery, Gunma Prefectural Cancer Center, Ota, Japan; 11Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan; 12Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Japan; 13Department of Diagnostic Pathology, Gunma University, Graduate School of Medicine, Maebashi, Japan; 14Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Maebashi, Japan
Publisher Copyright:
© 2020 International Institute of Anticancer Research. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Background: Pulmonary pleomorphic carcinoma (PPC) is a rare aggressive neoplasm, with dismal prognosis. Whether tumor immunity is associated with the progressive biological behavior of PPC remains unclear. The purpose of this study was to examine the prognostic significance of tumor immunity-related markers such as programmed death-1 ligand (PD-L1) and CD4+ or CD8+ tumor-infiltrating lymphocytes (TILs) in patients with surgically resected PPC. Patients and Methods: Ninety-nine patients with surgically resected PPC were assessed by immunohistochemistry. The expression of PDL1, CD4, and CD8 was examined in specimens of the resected tumors. Results: PD-L1 was highly expressed in 61% (60/99) of lesions and high expression of CD4 and CD8 was identified in 42% (42/99) and 51% (51/99) of lesions, respectively. There was no relationship between the expression PD-L1 and the numbers of CD4+ or CD8+ TILs. The expression of PD-L1 was not identified as a significant prognostic marker; however, a low number of CD4+ TILs was identified as an independent marker for predicting a worse outcome after surgical resection of PPC, especially in patients with an epithelial component of adenocarcinoma or early stage of disease. By univariate analysis, a low number of CD8+ TILs was found to be a significant prognostic marker linked to poor overall survival in patients with non-adenocarcinoma components. Conclusion: A low number of CD4+ TILs is an independent marker for predicting a favorable prognosis after surgical resection in patients with PPC, especially in patients with adenocarcinoma components or early stage of disease.
AB - Background: Pulmonary pleomorphic carcinoma (PPC) is a rare aggressive neoplasm, with dismal prognosis. Whether tumor immunity is associated with the progressive biological behavior of PPC remains unclear. The purpose of this study was to examine the prognostic significance of tumor immunity-related markers such as programmed death-1 ligand (PD-L1) and CD4+ or CD8+ tumor-infiltrating lymphocytes (TILs) in patients with surgically resected PPC. Patients and Methods: Ninety-nine patients with surgically resected PPC were assessed by immunohistochemistry. The expression of PDL1, CD4, and CD8 was examined in specimens of the resected tumors. Results: PD-L1 was highly expressed in 61% (60/99) of lesions and high expression of CD4 and CD8 was identified in 42% (42/99) and 51% (51/99) of lesions, respectively. There was no relationship between the expression PD-L1 and the numbers of CD4+ or CD8+ TILs. The expression of PD-L1 was not identified as a significant prognostic marker; however, a low number of CD4+ TILs was identified as an independent marker for predicting a worse outcome after surgical resection of PPC, especially in patients with an epithelial component of adenocarcinoma or early stage of disease. By univariate analysis, a low number of CD8+ TILs was found to be a significant prognostic marker linked to poor overall survival in patients with non-adenocarcinoma components. Conclusion: A low number of CD4+ TILs is an independent marker for predicting a favorable prognosis after surgical resection in patients with PPC, especially in patients with adenocarcinoma components or early stage of disease.
UR - http://www.scopus.com/inward/record.url?scp=85077470040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077470040&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13948
DO - 10.21873/anticanres.13948
M3 - Article
C2 - 31892575
AN - SCOPUS:85077470040
VL - 40
SP - 261
EP - 269
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 1
ER -